Physician profile
Igor E Matwijiw
NPI 1114911369
$20,432.04
in general payments reported to CMS, 2019-2025
19 companies · $123 in 2025
The $123 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $17K · 2020: $2,581 · 2021: $27.74 · 2022: $446 · 2023: $98.30 · 2024: $68.71 · 2025: $123.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $290.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $289.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $12,529.21 | 2019-2025 | Ozempic, Rybelsus |
| Amgen INC. | $6,473.40 | 2019-2025 | Evenity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $326.98 | 2019-2022 | |
| Lilly USA, LLC | $258.26 | 2019-2022 | |
| Abbott Laboratories | $240.48 | 2019-2023 | Freestyle Libre 3 |
| Sanofi-Aventis U.S. LLC | $176.83 | 2019-2023 | |
| Merck Sharp & Dohme LLC | $91.12 | 2019-2020 | |
| Tandem Diabetes Care, INC. | $44.22 | 2019-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Bayer Healthcare Pharmaceuticals INC. | $41.28 | 2024-2025 | |
| Janssen Pharmaceuticals, INC | $41.17 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $34.47 | 2021-2022 | |
| Xeris Pharmaceuticals, INC. | $32.40 | 2022-2023 | Gvoke Hypopen |
| Radius Health, INC. | $28.60 | 2019 | |
| Dexcom, INC. | $28.24 | 2022 | |
| Astrazeneca Pharmaceuticals Lp | $20.31 | 2022 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Madrigal Pharmaceuticals | $19.45 | 2025 | Rezdiffra |
| Antares Pharma, INC. | $18.09 | 2022 | |
| Nevro Corp. | $14.82 | 2022 | |
| Amarin Pharma, INC. | $12.71 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Igor Matwijiw listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.